Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 501

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Fritsch, Christine, Huang, Alan, Chatenay-Rivauday, Christian, Schnell, Christian, Reddy, Anupama, Liu, Manway, Kauffmann, Audrey, Guthy, Daniel, Erdmann, Dirk, De Pover, Alain, Furet, Pascal, Gao, Hui, Ferretti, Stephane, Wang, Youzhen, Trappe, Joerg, Brachmann, Saskia M., Maira, Sauveur-Michel, Wilson, Christopher, Boehm, Markus, Garcia-Echeverria, Carlos, Chene, Patrick, Wiesmann, Marion, Cozens, Robert, Lehar, Joseph, Schlegel, Robert, Caravatti, Giorgio, Hofmann, Francesco, Sellers, William R.·2014·Molecular Cancer Therapeutics

Abstract

Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects associated with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family. Here, we report the biologic properties of the 2-aminothiazole derivative NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms. The compound selectivity combined with excellent drug-like properties translates to dose- and time-dependent inhibition of PI3Kα signaling in vivo, resulting in robust therapeutic efficacy and tolerability in PIK3CA-dependent tumors. Novel targeted therapeutics such as NVP-BYL719, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients. Here, we also describe the application of the Cancer Cell Line Encyclopedia as a preclinical platform to refine the patient stratification strategy for NVP-BYL719 and found that PIK3CA mutation was the foremost positive predictor of sensitivity while revealing additional positive and negative associations such as PIK3CA amplification and PTEN mutation, respectively. These patient selection determinants are being assayed in the ongoing NVP-BYL719 clinical trials. Mol Cancer Ther; 13(5); 1117–29. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-13-0865

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 501

Metadata

Authors
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., Furet, P., Gao, H., Ferretti, S., Wang, Y., Trappe, J., Brachmann, S. M., Maira, S.-M., Wilson, C., Boehm, M., Garcia-Echeverria, C., Chene, P., Wiesmann, M., Cozens, R., Lehar, J., Schlegel, R., Caravatti, G., Hofmann, F., & Sellers, W. R.
Venue
Molecular Cancer Therapeutics
Published
2014-05-01
Volume
13
Issue
5
Pages
1117-1129
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2101982508
Cited by
501
References
40
FWCI
13.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0865
The paper
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., Furet, P., Gao, H., Ferretti, S., Wang, Y., Trappe, J., Brachmann, S. M., Maira, S.-M., Wilson, C., Boehm, M., . . . Sellers, W. R. (2014). Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0865

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.